Synthesis, characterization, and application of novel biodegradable self-assembled 2-(N-phthalimido) ethyl-palmitate nanoparticles for cancer therapy
Source abstract
Abstract
We report the synthesis of novel biodegradable nanoparticles (NPs) which can kill the cancer cells without any additional drug loading. The NP was a self-assembled form of a phthalimide based conjugate, in which the phthalimide moiety was responsible for the anticancer activity. We describe the synthesis of a novel 2-(N-phthalimido) ethyl palmitate (PHEP-Pal) conjugate and subsequent preparation of NPs by a simple self assembly process. The successful synthesis of conjugate was confirmed by various characterization studies including nuclear magnetic resonance spectroscope, Fourier transform infrared spectroscope, TOF-liquid chromatography mass spectroscope, differential scanning calorimetry, and X-ray diffraction unit. The synthesis, shape, size, and size distribution of PHEP-Pal NPs were determined by transmission electron microscope, atomic force microscope, and dynamic light scattering technique. Finally, cell culture studies using A549 and HeLa cells were done to evaluate the anticancer effect of PHEP-Pal NPs, which demonstrated the potency of these NPs for use in cancer chemotherapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (25)
Show source-provided references
1. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–165910.1016/j.addr.2004.02.014 ↗
2. Chan SH, Lam KH, Chiu CH et al (2009) The preparation and in vitro antiproliferative activity of phthalimide based ketones on MDAMB-231 and SKHep-1 human carcinoma cell lines. Eur J Med Chem 44:2736–274010.1016/j.ejmech.2008.10.024 ↗
3. Corti M, Cantu L, Brocca P et al (2007) Self-assembly in glycolipids. Curr Opin Colloid Interface Sci 12:148–15410.1016/j.cocis.2007.05.002 ↗
4. Das RK, Kasoju N, Bora U (2009) Encapsulation of curcumin in alginate–chitosan–pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine. doi: 10.1016/j.nano.2009.05.00910.1016/j.nano.2009.05.009 ↗
5. Feng SS, Chien (2003) Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 58:14–4087
6. Feng SS, Mu L, Win KY et al (2004) Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 11:413–42410.2174/0929867043455909 ↗
7. Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7:1041–105310.1517/14656566.7.8.1041 ↗
8. Gu FX, Karnik R, Wang AZ et al (2007) Targeted nanoparticles for cancer therapy. Nanotoday 2:14–21
9. Hall IH, Wong OT, Scovill JP (1995) The cytotoxicity of N-pyridinyl and N-quinolinyl substituted derivatives of phthalimide and succinimide. Biomed Pharmacother 5:251–25810.1016/0753-3322(96)82631-X ↗
10. Hou D, Xie C, Huang K et al (2003) The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24:1781–178510.1016/S0142-9612(02)00578-1 ↗
11. Janes KA, Fresneau MP, Marazuela A et al (2001) Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release 73:255–26710.1016/S0168-3659(01)00294-2 ↗
12. Li L, Braiteh FS, Kurzrock R (2005) Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104:1322–133110.1002/cncr.21300 ↗
13. Lima LM, Castro P, Machado AL et al (2002a) Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg Med Chem 10:3067–307310.1016/S0968-0896(02)00152-9 ↗
14. Lima ML, de Brito FCF, de Souza SD et al (2002b) Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorg Med Chem Lett 12:1533–153510.1016/S0960-894X(02)00203-2 ↗
15. Maeda H, Wu J, Sawa T et al (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–28410.1016/S0168-3659(99)00248-5 ↗
16. Miele E, Spinelli GP, Miele E et al (2009) Albumin-bound formulation of paclitaxel (Abraxane (R) ABI-007) in the treatment of breast cancer. Int J Nanomed 4:99–10510.1504/IJNM.2009.028116 ↗
17. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–6310.1016/0022-1759(83)90303-4 ↗
18. Nasongkla N, Shuai X, Ai H et al (2004) cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl 43:6323–632710.1002/anie.200460800 ↗
19. Noguchi T, Fujimoto H, Sano H et al (2005) Angiogenesis inhibitors derived from thalidomide. Bioorg Med Chem Lett 15:5509–551310.1016/j.bmcl.2005.08.086 ↗
20. Noguchi-Yachide T, Aoyama A, Makishima M et al (2007) Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett 17:3957–396110.1016/j.bmcl.2007.04.090 ↗
21. Sahu A, Bora U, Kasoju N et al (2008a) Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 4:1752–176110.1016/j.actbio.2008.04.021 ↗
22. Sahu A, Kasoju N, Bora U (2008b) Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules 9:2905–291210.1021/bm800683f ↗
23. Shinji C, Nakamura T, Maeda S et al (2005) Design and synthesis of phthalimide-type histone deacetylase inhibitors. Bioorg Med Chem Lett 15:4427–443110.1016/j.bmcl.2005.07.048 ↗
24. Wang SN, Deng YH, Xu H et al (2006) Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. Eur J Pharm Biopharm 62:32–3810.1016/j.ejpb.2005.07.004 ↗
25. Zhang L, Chan JM, Gu FX et al (2008) Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696–170210.1021/nn800275r ↗